 |
|
|
||||||||||||||
 |
|
|
Tethys is committed to providing the media with timely and accurate information, and we've assembled the following resources to help you learn more about the company and our products.
If you have questions or wish to speak with a representative of the company, please contact a member of the Tethys communications team:
Jay Kerzner, Director of Communications 510-420-6746, jkerzner@tethysbio.com
Hal Mackins, Media Relations for Tethys 415-677-2747, hal.mackins@fkhealth.com
Nov 9, 2009
Tethys Bioscience Raises $25 Million in Series D Financing
The financing round is led by aeris Capital with George Rehm taking a seat on the Tethys board.
Oct 20, 2009
Gazing into the Future
(Journal of Life Sciences, Fall 2009)
Sep 24, 2009
A preemptive strike on diabetes: Emeryville's Tethys Biosciences rolls out pre-diabetes test
Tethys Bioscience featured in the September/October 2009 issue of Healthcare Journal of Northern California.
Aug 31, 2009
Personnel Additions and Promotions at Tethys Bioscience
Management Team in Position for Full Commercialization of its Line of Personalized-Prevention Diagnostics
Jul 15, 2009
Peer-Reviewed Publications Demonstrate Tethys Bioscience's Ability to Identify those at Highest Risk of Developing Type 2 Diabetes within Five Years
Diabetes journals publish two definitive papers supporting both the science behind and the clinical performance of lead product, the PreDx™ Diabetes Risk Score (DRS)
Jun 7, 2009
New Data in Support of Tethys Bioscience's PreDx™ Diabetes Risk Score Presented at ADA Scientific Sessions
New data support cost-effectiveness and clinical utility of a risk assessment test for type 2 diabetes